- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1558-822X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The Role of Early Molecular Response in the Management of Chronic Phase CML ; day:12 ; month:4 ; year:2017 ; pages:1-6
Current hematologic malignancy reports ; (12.4.2017), 1-6
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Harrington, Patrick
- Beteiligte Personen und Organisationen
-
Kizilors, Aytug
Lavallade, Hugues de
SpringerLink (Online service)
- DOI
-
10.1007/s11899-017-0375-0
- URN
-
urn:nbn:de:1111-201704293302
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Harrington, Patrick
- Kizilors, Aytug
- Lavallade, Hugues de
- SpringerLink (Online service)
Ähnliche Objekte (12)
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
CML
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study
Molecular monitoring in CML—a modern example of an old proverb
BCAT1 contributes to the development of TKI-resistant CML
STAT3-mediated therapy resistance of malignant stem cells in chronic myeloid leukemia (CML)
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
CML
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study
Molecular monitoring in CML—a modern example of an old proverb
BCAT1 contributes to the development of TKI-resistant CML
STAT3-mediated therapy resistance of malignant stem cells in chronic myeloid leukemia (CML)
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
CML
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study
Molecular monitoring in CML—a modern example of an old proverb
BCAT1 contributes to the development of TKI-resistant CML
STAT3-mediated therapy resistance of malignant stem cells in chronic myeloid leukemia (CML)